Price Action Alert: Is Kindred Biosciences Inc a Sell? The Stock Declines Again

Price Action Alert: Is Kindred Biosciences Inc a Sell? The Stock Declines Again

The stock of Kindred Biosciences Inc (NASDAQ:KIN) is a huge mover today! About 93,096 shares traded hands. Kindred Biosciences Inc (NASDAQ:KIN) has risen 26.03% since April 13, 2016 and is uptrending. It has outperformed by 22.10% the S&P500.
The move comes after 8 months negative chart setup for the $85.27M company. It was reported on Nov, 15 by We have $4.01 PT which if reached, will make NASDAQ:KIN worth $8.53M less.

Kindred Biosciences Inc (NASDAQ:KIN) Ratings Coverage

Out of 2 analysts covering Kindred Biosciences (NASDAQ:KIN), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Kindred Biosciences has been the topic of 2 analyst reports since November 17, 2015 according to StockzIntelligence Inc. BMO Capital Markets downgraded Kindred Biosciences Inc (NASDAQ:KIN) on Tuesday, November 17 to “Market Perform” rating. As per Tuesday, November 1, the company rating was initiated by Ladenburg Thalmann.

According to Zacks Investment Research, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.”

Insitutional Activity: The institutional sentiment increased to 3.13 in Q2 2016. Its up 2.48, from 0.65 in 2016Q1. The ratio is positive, as 3 funds sold all Kindred Biosciences Inc shares owned while 5 reduced positions. 4 funds bought stakes while 21 increased positions. They now own 25.54 million shares or 107.22% more from 12.33 million shares in 2016Q1.
Fmr Limited Liability Company holds 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN) for 219,950 shares. Moreover, Tower Research Capital Ltd Llc (Trc) has 0% invested in Kindred Biosciences Inc (NASDAQ:KIN) for 1,455 shares. Jackson Park Cap Lc last reported 0.37% of its portfolio in the stock. Blackrock Institutional Trust Company Na reported 62,182 shares or 0% of all its holdings. Blackrock Japan accumulated 3,327 shares or 0% of the stock. Jpmorgan Chase & has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Norman Fields Gottscho Capital Ltd Liability Co accumulated 13,900 shares or 0.03% of the stock. Renaissance Tech Limited Liability Company has 302,700 shares for 0% of their US portfolio. Walleye Trading Ltd Liability has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Goldman Sachs accumulated 28,372 shares or 0% of the stock. Moreover, Blackrock Management Ltd Liability Corporation has 0% invested in Kindred Biosciences Inc (NASDAQ:KIN) for 2,994 shares. Mufg Americas Hldgs Corp has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Ny State Common Retirement Fund has invested 0% of its portfolio in Kindred Biosciences Inc (NASDAQ:KIN). Park West Asset Mngmt Limited Liability holds 1.95M shares or 0.7% of its portfolio. Vanguard Gru holds 0% or 432,937 shares in its portfolio.

More notable recent Kindred Biosciences Inc (NASDAQ:KIN) news were published by: which released: “Kindred Biosciences Announces Third Quarter 2016 Financial Results” on November 07, 2016, also with their article: “Kindred Biosciences to Present at 2016 Ladenburg Thalmann Healthcare Conference” published on September 20, 2016, published: “News Kindred Biosciences Inc.KIN” on December 07, 2013. More interesting news about Kindred Biosciences Inc (NASDAQ:KIN) were released by: and their article: “Kindred Biosciences Submits New Animal Drug Application Technical Section for …” published on August 22, 2016 as well as‘s news article titled: “Kindred Biosciences Submits Final Major New Animal Drug Application Technical …” with publication date: September 30, 2016.

KIN Company Profile

Kindred Biosciences, Inc., incorporated on September 25, 2012, is a development-stage biopharmaceutical company. The Firm is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Firm is developing product candidates for over 20 indications and focused on small molecule products, and canine and feline biologics products. The Company’s biologic product candidates are based on therapies and targets, for which products have been commercialized for humans. The Firm is developing antibodies that target canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment